Filtered By:
Cancer: Brain Cancers

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 538 results found since Jan 2013.

Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells
Conclusion The siRNA-induced AKT3 and PI3KCA mRNA knockdown in combination with TMZ and BCNU inhibited proliferation and induced apoptosis and autophagy in T98G cells. Thus, knockdown of these genes in combination with TMZ and BCNU may offer a novel therapeutic strategy to more effectively control the growth of human GBM cells, but further studies are necessary to confirm a positive phenomenon for the treatment of GBM.
Source: BioDrugs - February 22, 2016 Category: Drugs & Pharmacology Source Type: research

Silencing of ataxia-telangiectasia mutated by siRNA enhances the in vitro and in vivo radiosensitivity of glioma.
In conclusion, silencing of ATM via the siRNA technique could improve the in vitro and in vivo radiosensitivity of glioma cells. PMID: 27108486 [PubMed - as supplied by publisher]
Source: Oncology Reports - April 27, 2016 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Silencing of ATM expression by siRNA technique contributes to glioma stem cell radiosensitivity in vitro and in vivo.
In conclusion, silencing of ATM via the siRNA technique improved radiosensitivity of GSCs both in vitro and in vivo. PMID: 28560406 [PubMed - as supplied by publisher]
Source: Oncology Reports - June 2, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy
Biomaterials. 2022 Jun 22;287:121645. doi: 10.1016/j.biomaterials.2022.121645. Online ahead of print.ABSTRACTGlioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor with a high mortality rate. Immunotherapy has achieved promising clinical results in multiple cancers, but shows unsatisfactory outcome in GBM patients, and poor drug delivery across the blood-brain barrier (BBB) is believed to be one of the main limitations that hinder the therapeutic efficacy of drugs. Herein, a new cationic lipid nanoparticle (LNP) that can efficiently deliver siRNA across BBB and target mouse brain is prepared fo...
Source: Biomaterials - July 2, 2022 Category: Materials Science Authors: Shuhan Liu Ji Liu Haisong Li Kuirong Mao Haorui Wang Xiandi Meng Jialiang Wang Chenxi Wu Hongmei Chen Xin Wang Xiuxiu Cong Yue Hou Ye Wang Ming Wang Yong-Guang Yang Tianmeng Sun Source Type: research

Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains.
In this study, we aim to evaluate the safety of MGMT-siRNA/cationic liposome complexes and determine whether the convection-enhanced delivery of these complexes is suitable for clinical use by undertaking preclinical testing in laboratory animals. No significant adverse events were observed in rats receiving infusions of MGMT-siRNA/cationic liposome complex directly into the brain with or without TMZ administration. A pig which received the complex administered by CED also showed no evidence of neurological dysfunction or histological abnormalities. However, the complex did not appear to achieve effective distribution by C...
Source: American Journal of Translational Research - November 14, 2014 Category: Research Tags: Am J Transl Res Source Type: research

siRNA-mediated inhibition of endogenous brain ‑derived neurotrophic factor gene modulates the biological behavior of HeLa cells.
siRNA-mediated inhibition of endogenous brain‑derived neurotrophic factor gene modulates the biological behavior of HeLa cells. Oncol Rep. 2017 May;37(5):2751-2760 Authors: Sun CY, Chu ZB, Huang J, Chen L, Xu J, Xu AS, Li JY, Hu Y Abstract Brain-derived neurotrophic factor (BDNF) is expressed in a number of neural and non-neuronal tumors. The present study investigated the effect of endogenous BDNF on the biological behavior of cervix cancer cells using small interfering RNA (siRNA). HeLa, a cervix cancer cell line with high expression of BDNF, was used as a living model to screen out the effective s...
Source: Oncology Reports - April 14, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

MnAl-Layered Double Hydroxide Nanoparticles as a Dual-functional Platform for Magnetic Resonance Imaging and siRNA Delivery.
Abstract Multifunctional nanoparticles for cancer theranosis have been widely explored for effective cancer detection and therapy. In this research, dually functionalised manganese-based layered double hydroxide nanoparticles (Mn-LDHs) have been examined as an effective anticancer drug/gene delivery system and T1-weighted magnetic resonance imaging (MRI) modality for brain cancer theranostics. Such Mn-LDHs have been shown to accommodate dsDNA/siRNAs and efficiently deliver to Neuro-2a cells (N2a). Mn-LDHs have also shown high biocompatibility with low cytotoxicity. Importantly, the cell death-siRNA (CD-siRNA) deli...
Source: Chemistry - August 1, 2017 Category: Chemistry Authors: Zuo H, Chen W, Li B, Xu K, Cooper H, Gu Z, Xu ZP Tags: Chemistry Source Type: research

NT-09 * CO-DELIVERY OF siRNA AND CHEMOTHERAPY; A NEW APPROACH FOR GBM TREATMENT USING A NANOCARRIERS SYSTEM
Over the past decade, progress in genomics and proteomics has paved the way for identifying promising macromolecular therapeutics including small RNAs, peptides and proteins. Still, the vast majority of leading drugs candidates for the treatment of CNS diseases is ineffective, mainly due to restricted passages across the BBB. Nanoparticles packaging of therapy is of particular interest for its potential to treat brain tumors, due to their ability to transport drugs through the BBB, while improving the performance of drugs by decreasing systemic and local toxicity. We chose GBM known for its poor prognosis, as a model for b...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Cohen, Z. R., Peshes-Yeloz, N., Voll, A., Zibly, Z., Peer, D. Tags: NOVEL THERAPEUTICS (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research

NT-16 * NANOPARTICLE-MEDIATED DELIVERY OF ANTI-Ape1 siRNA SENSITIZES PEDIATRIC BRAIN TUMOR CELLS TO RADIATION THERAPY BY INHIBITING DNA REPAIR
Pediatric brain tumors are the leading cause of death in children, and survival is frequently accompanied by one or more radiation-induced adverse developmental and psychosocial sequelae. Radiotherapy (RT) is an integral component of the treatment for medulloblastoma (MB) and the only effective adjuvant therapy for ependymoma (EP). Therefore, there is an urgent need to develop strategies to enhance the tumoricidal action of RT while sparing adjacent normal tissue. The multifunctional DNA repair protein Ape1/Ref-1 has been implicated in conferring radiation resistance in pediatric brain tumors. However, inhibiting Ape1 acti...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Kievit, F., Stephen, Z., Wang, K., Dayringer, C., Ellenbogen, R., Silber, J., Zhang, M. Tags: NOVEL THERAPEUTICS (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research

Cancers, Vol. 11, Pages 333: Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model
r Donat Kögel Glioblastoma (GBM), WHO grade IV, is the most aggressive primary brain tumor in adults. The median survival time using standard therapy is only 12–15 months with a 5-year survival rate of around 5%. Thus, new and effective treatment modalities are of significant importance. Signal transducer and activator of transcription 3 (Stat3) is a key signaling protein driving major hallmarks of cancer and represents a promising target for the development of targeted glioblastoma therapies. Here we present data showing that the therapeutic application of siRNAs, formulated in nanoscale lipopolyplexe...
Source: Cancers - March 7, 2019 Category: Cancer & Oncology Authors: Benedikt Linder Ulrike Weirauch Alexander Ewe Anja Uhmann Volker Seifert Michel Mittelbronn Patrick N. Harter Achim Aigner Donat K ögel Tags: Article Source Type: research

Antiproliferative activity of CD44 siRNA-PEI-PEG nanoparticles in glioblastoma: involvement of AKT signaling
CONCLUSION AND IMPLICATIONS: Our results suggest that PEI-PEG-loaded CD44 siRNA may attenuate the cell cycle by suppressing AKT signaling pathway.PMID:34909046 | PMC:PMC8621842 | DOI:10.4103/1735-5362.329928
Source: Cell Research - December 15, 2021 Category: Cytology Authors: Parvaneh Mahinfar Ahad Mokhtarzadeh Behzad Baradaran Elham Siasi Torbati Source Type: research

Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy
In conclusion, HA/DP7-C is a potential intranasal delivery system for siRNAs in glioma therapy.PMID:34973309 | DOI:10.1016/j.jconrel.2021.12.034
Source: Cancer Control - January 1, 2022 Category: Cancer & Oncology Authors: YuLing Yang XueYan Zhang SiWen Wu Rui Zhang BaiLing Zhou XiaoYu Zhang Lin Tang Yaomei Tian Ke Men Li Yang Source Type: research

Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?
Abstract RNA interference has been envisaged as a powerful tool for molecular and clinical investigation with a great potential for clinical applications. In recent years, increased understanding of cancer biology and stem cell biology has dramatically accelerated the development of technology for cell and gene therapy in these areas. This paper is a review of the most recent report of innovative use of siRNA to benefit several central nervous system diseases. Furthermore, a description is made of innovative strategies of delivery into the brain by means of viral and non-viral vectors with high potential for trans...
Source: Cellular and Molecular Life Sciences : CMLS - March 19, 2013 Category: Cytology Authors: Gherardini L, Bardi G, Gennaro M, Pizzorusso T Tags: Cell Mol Life Sci Source Type: research

PYGB siRNA inhibits the cell proliferation of human osteosarcoma cell lines.
In conclusion, PYGB siRNA exerted an inhibitory effect on the cell viability of the human osteosarcoma cells MG63 and HOS by blocking the Caspase/Bcl and CDK1 signaling pathway, highlighting novel potential therapeutic methods for treating osteosarcoma. PMID: 29845265 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - June 2, 2018 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma
AbstractGlioblastoma is one of the most aggressive types of brain tumor. Epidermal growth factor receptors (EGFRs) are overexpressed in glioma, and EGFR amplifications and mutations lead to rapid proliferation and invasion. EGFR-targeted therapy might be an effective treatment for glioma. Gefitinib (Ge) is an EGFR tyrosine kinase inhibitor (TKI), and Golgi phosphoprotein 3 (GOLPH3) expression is associated with worse glioma prognosis. Downregulation of GOLPH3 could promote EGFR degradation. Here, an angiopep-2 (A2)-modified cationic lipid-poly (lactic-co-glycolic acid) (PLGA) nanoparticle (A2-N) was developed that can rele...
Source: Journal of Molecular Medicine - October 29, 2019 Category: Molecular Biology Source Type: research